文献速递儿科与产科急症重症综合管理与镇静镇痛

澳大利亚公共卫生系统危重婴幼儿及儿童疑似单基因病超快速外显子测序可行性研究

Feasibility of Ultra-Rapid Exome Sequencing in Critically Ill Infants and Children With Suspected Monogenic Conditions in the Australian Public Health Care System.
PubMed 文献 · JAMA · 2020-01-01
一句话结论在澳大利亚12家医院,危重患儿疑似单基因病行超快速外显子测序,标本接收至报告平均3.3天,51%获分子诊断,76%诊断者临床管理受影响。

这项描述性可行性研究纳入2018年3月至2019年2月澳大利亚12家医院108例危重患儿(中位年龄28天),评估超快速外显子测序在公共卫生系统中的可行性。从标本接收到报告平均3.3天(95%CI 3.2-3.5天),86%报告在死亡或出院前发出。55例(51%)获得分子诊断,其中42/55(76%)诊断者与6/53(11%)未诊断者临床管理被认为受影响。作者认为该检测在澳大利亚公共卫生系统危重患儿中可行,但需进一步研究其临床价值及在其他医疗环境中的普适性。

要点

  • 108例危重患儿中,标本接收至超快速外显子测序报告平均3.3天(95%CI 3.2-3.5天),中位3天(范围2-7天)。
  • 51%(55/108)获得分子诊断,其中20%(11/55)诊断来自线粒体基因组测序、拷贝数分析、国际数据库新基因关联、额外表型及RNA分析等增强方法。
  • 76%(42/55)诊断者与11%(6/53)未诊断者中,超快速外显子测序结果被认为影响临床管理。
  • 12例(11%)启动靶向治疗,14例(13%)转向姑息治疗,19例(18%)启动特定并发症监测。
  • 86%(93/108)报告在死亡或出院前发出,入院至报告平均17.5天(95%CI 14.6-21.1天)。

适用人群与场景

  • 澳大利亚12家医院收治的危重儿科患者,疑似单基因病,2018年3月至2019年2月纳入,数据收集至2019年5月。
  • 纳入患者中位年龄28天(范围0天至17岁),34%为女性,57%来自新生儿重症监护室,33%来自儿科重症监护室,9%来自其他病房。

处置流程与药物剂量

  • 采用超快速外显子测序,通过强调沟通反馈、标准化流程、协调、分布式领导和集体学习的正式实施策略促进应用。
  • 在标准外显子测序分析基础上,对部分患者加用线粒体基因组测序分析、基于外显子测序的拷贝数分析、利用国际数据库识别新基因-疾病关联、额外表型及RNA分析,使11例(20%)诊断得以确立。

研究设计与关键结果

  • 描述性可行性研究,108例危重儿科患者,12家澳大利亚医院,超快速外显子测序。
  • 主要终点:标本接收至报告平均3.3天(95%CI 3.2-3.5天),中位3天(范围2-7天)。
  • 分子诊断率51%(55/108)。
  • 55例诊断者中42例(76%)与53例未诊断者中6例(11%)的超快速外显子测序结果被认为影响临床管理。
  • 12例(11%)启动靶向治疗,14例(13%)治疗转向姑息治疗,19例(18%)启动特定并发症监测。
  • 入院至报告平均17.5天(95%CI 14.6-21.1天),93份报告(86%)在死亡或出院前发出。

证据类型、等级与局限

  • 证据类型:描述性可行性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该研究提示在澳大利亚公共卫生系统危重儿科疑似单基因病患者中开展超快速基因组检测是可行的。
  • 作者指出,需进一步研究以理解此类检测的临床价值,以及研究结果在其他医疗环境中的普适性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Widespread adoption of rapid genomic testing in pediatric critical care requires robust clinical and laboratory pathways that provide equitable and consistent service across health care systems.

OBJECTIVE: To prospectively evaluate the performance of a multicenter network for ultra-rapid genomic diagnosis in a public health care system.

DESIGN, SETTING, AND PARTICIPANTS: Descriptive feasibility study of critically ill pediatric patients with suspected monogenic conditions treated at 12 Australian hospitals between March 2018 and February 2019, with data collected to May 2019. A formal implementation strategy emphasizing communication and feedback, standardized processes, coordination, distributed leadership, and collective learning was used to facilitate adoption.

EXPOSURES: Ultra-rapid exome sequencing.

MAIN OUTCOMES AND MEASURES: The primary outcome was time from sample receipt to ultra-rapid exome sequencing report. The secondary outcomes were the molecular diagnostic yield, the change in clinical management after the ultra-rapid exome sequencing report, the time from hospital admission to the laboratory report, and the proportion of laboratory reports returned prior to death or hospital discharge.

RESULTS: The study population included 108 patients with a median age of 28 days (range, 0 days to 17 years); 34% were female; and 57% were from neonatal intensive care units, 33% were from pediatric intensive care units, and 9% were from other hospital wards. The mean time from sample receipt to ultra-rapid exome sequencing report was 3.3 days (95% CI, 3.2-3.5 days) and the median time was 3 days (range, 2-7 days). The mean time from hospital admission to ultra-rapid exome sequencing report was 17.5 days (95% CI, 14.6-21.1 days) and 93 reports (86%) were issued prior to death or hospital discharge. A molecular diagnosis was established in 55 patients (51%). Eleven diagnoses (20%) resulted from using the following approaches to augment standard exome sequencing analysis: mitochondrial genome sequencing analysis, exome sequencing-based copy number analysis, use of international databases to identify novel gene-disease associations, and additional phenotyping and RNA analysis. In 42 of 55 patients (76%) with a molecular diagnosis and 6 of 53 patients (11%) without a molecular diagnosis, the ultra-rapid exome sequencing result was considered as having influenced clinical management. Targeted treatments were initiated in 12 patients (11%), treatment was redirected toward palliative care in 14 patients (13%), and surveillance for specific complications was initiated in 19 patients (18%).

CONCLUSIONS AND RELEVANCE: This study suggests feasibility of ultra-rapid genomic testing in critically ill pediatric patients with suspected monogenic conditions in the Australian public health care system. However, further research is needed to understand the clinical value of such testing, and the generalizability of the findings to other health care settings.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Lunke S, Eggers S, Wilson M, et al. Feasibility of Ultra-Rapid Exome Sequencing in Critically Ill Infants and Children With Suspected Monogenic Conditions in the Australian Public Health Care System. JAMA. 2020. PMID: 32573669. doi:10.1001/jama.2020.7671

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。